




RealRate

PHARMACEUTICAL 2022

Whitehawk Therapeutics Inc
Rank 214 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Whitehawk Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Whitehawk Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Whitehawk Therapeutics Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 308%, being 33% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	151,272
Cost of Goods Sold	0
Intangible Assets	3,811
Liabilities, Current	15,273
Liabilities, Non-Current	474
Other Assets	2,770
Other Compr. Net Income	-647
Other Expenses	74,158
Other Liabilities	5,757
Other Net Income	1,129
Other Revenues	1,120
Property and Equipment	57
Research and Development	19,670
Selling, General and Administrative Expense	18,511

Output Variable	Value in 1000 USD
Assets	157,910
Liabilities	21,504
Expenses	112,339
Revenues	1,120
Stockholders Equity	136,406
Net Income	-110,090
Comprehensive Net Income	-110,414
BaseVar	147,324
ECR before LimitedLiability	208%
Economic Capital Ratio	308%